Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202930 | 0.90 | HRH3 (0.33) | SIGMAR1HRH3KCNH2OPRL1 | |
| SCHEMBL11001122 | 0.81 | SIGMAR1 (0.43) | SIGMAR1HRH3KCNH2 | |
| SCHEMBL736315 | 0.81 | KDM4E (0.41) | HRH3POLB | |
| SCHEMBL13227552 | 0.81 | KDM4E (0.41) | HRH3POLB | |
| SCHEMBL26691266 | 0.81 | SIGMAR1 (0.35) | SIGMAR1HRH3KCNH2POLBOPRL1 | |
| SCHEMBL13620647 | 0.81 | ALDH1A1 (0.38) | HRH3OPRL1 | |
| SCHEMBL10863656 | 0.79 | HRH3 (0.34) | SIGMAR1HRH3KCNH2OPRL1 | |
| SCHEMBL11942149 | 0.79 | OPRL1 (0.31) | OPRL1 | |
| SCHEMBL18202974 | 0.79 | HRH3 (0.46) | HRH3OPRL1 | |
| SCHEMBL4481058 | 0.79 | HRH3 (0.34) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | SIGMAR1 3391/4885HRH3 2982/4885KCNH2 3866/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | SIGMAR1 3391/4885HRH3 2982/4885KCNH2 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.